MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.36
+0.10
+0.66%
After Hours: 15.36 0 0.00% 16:35 11/15 EST
OPEN
15.38
PREV CLOSE
15.26
HIGH
15.49
LOW
15.11
VOLUME
261.75K
TURNOVER
--
52 WEEK HIGH
16.59
52 WEEK LOW
5.14
MARKET CAP
1.40B
P/E (TTM)
-9.5309
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EPZM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EPZM News

  • These 36 Mass. firms made Deloitte's Technology Fast 500
  • American City Business Journals.11/07 11:08
  • The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment
  • Benzinga.11/05 11:54
  • Epizyme up 6% on funding deals
  • Seeking Alpha - Article.11/04 16:53
  • Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement
  • Benzinga.11/04 12:38

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About EPZM

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
More

Webull offers Epizyme Inc (EPZM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.